Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-22
2011-10-04
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S885000, C514S908000
Reexamination Certificate
active
08030301
ABSTRACT:
A method of inhibiting growth of a tumor cell in a mammal may include steps of administering to the mammal a first solution including a tumor-inhibiting methylol-containing compound, the first solution further including a first combination having a plurality of physiologically acceptable electrolytes or a second combination having at least one amino acid in combination with at least one physiologically acceptable electrolyte. Alternatively, another solution may be administered to the mammal containing a tumor-inhibiting methylol-containing compound, while concurrently administering to the mammal a further solution including the first combination with the plurality of physiologically acceptable electrolytes or the second combination with at least one said amino acid in combination with at least one physiologically acceptable electrolyte.
REFERENCES:
patent: 504243 (1893-08-01), Philippot
patent: 1039140 (1912-09-01), Kampfe
patent: 1188697 (1916-06-01), Steinberg
patent: 1461366 (1923-07-01), Mulford et al.
patent: 1676146 (1928-07-01), Krafft
patent: 2021465 (1935-11-01), Ritscher
patent: 2609960 (1952-09-01), Irwin
patent: 2643024 (1953-06-01), Cronheim
patent: 2760672 (1956-08-01), Cronheim
patent: 3598105 (1971-08-01), Cristaldi
patent: 3809064 (1974-05-01), Ziegler
patent: 3961443 (1976-06-01), Insalaco
patent: 4000830 (1977-01-01), French
patent: 4350156 (1982-09-01), Malchesky et al.
patent: 4467784 (1984-08-01), Lee et al.
patent: 4482077 (1984-11-01), Henderson
patent: 4626536 (1986-12-01), Pfirrmann
patent: 4654345 (1987-03-01), Cavanak
patent: 4828140 (1989-05-01), Henderson
patent: 4960415 (1990-10-01), Reinmüller
patent: 5077281 (1991-12-01), Reinmüller
patent: 5167960 (1992-12-01), Ito et al.
patent: 5176651 (1993-01-01), Allgood et al.
patent: 5191900 (1993-03-01), Mishra
patent: 5208018 (1993-05-01), Gough
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5262403 (1993-11-01), Nicolson et al.
patent: 5362754 (1994-11-01), Raad et al.
patent: 5416091 (1995-05-01), King
patent: 5441481 (1995-08-01), Mishra et al.
patent: 5554148 (1996-09-01), Aebischer et al.
patent: 5593665 (1997-01-01), Pfirrmann et al.
patent: 5696153 (1997-12-01), Ainsworth et al.
patent: 5725553 (1998-03-01), Moenning
patent: 5730045 (1998-03-01), Delaquis et al.
patent: 5749859 (1998-05-01), Powell
patent: 5763421 (1998-06-01), Caretto et al.
patent: 5819748 (1998-10-01), Pfirrmann
patent: 5881905 (1999-03-01), Brady
patent: 5889183 (1999-03-01), Herdeis et al.
patent: 5957038 (1999-09-01), Shimazaki
patent: 6011030 (2000-01-01), Pfirrmann
patent: 6029843 (2000-02-01), Kroscher et al.
patent: 6030358 (2000-02-01), Odland
patent: 6035766 (2000-03-01), Schirmer
patent: 6080397 (2000-06-01), Pfirrmann
patent: 6093180 (2000-07-01), Elsberry
patent: 6105811 (2000-08-01), Alfred
patent: 6117868 (2000-09-01), Pfirrmann
patent: 6166007 (2000-12-01), Sodemann
patent: 6258797 (2001-07-01), Lehner
patent: 6303596 (2001-10-01), Morrissey et al.
patent: 6429224 (2002-08-01), Calabresi et al.
patent: 6479481 (2002-11-01), Stendel et al.
patent: 6521616 (2003-02-01), Calabresi et al.
patent: 6546849 (2003-04-01), Shimazaki
patent: 6617333 (2003-09-01), Rabindran et al.
patent: 6688487 (2004-02-01), Oakes et al.
patent: 6815441 (2004-11-01), Stendel et al.
patent: 6821968 (2004-11-01), Pfirrmann
patent: 6995164 (2006-02-01), Calabresi et al.
patent: 7151099 (2006-12-01), Redmond et al.
patent: 7345039 (2008-03-01), Redmond et al.
patent: 2001/0031870 (2001-10-01), Soll et al.
patent: 2002/0052366 (2002-05-01), Calabresi et al.
patent: 2002/0091123 (2002-07-01), Redmond et al.
patent: 2002/0098164 (2002-07-01), Redmond et al.
patent: 2002/0111328 (2002-08-01), Redmond et al.
patent: 2002/0111345 (2002-08-01), Calabresi et al.
patent: 2002/0131935 (2002-09-01), Fisher et al.
patent: 2003/0027818 (2003-02-01), Redmond et al.
patent: 2003/0092707 (2003-05-01), Redmond et al.
patent: 2003/0195198 (2003-10-01), Stendal et al.
patent: 2004/0087579 (2004-05-01), Redmond et al.
patent: 2302720 (2000-09-01), None
patent: 2 393 159 (2001-06-01), None
patent: 2 393 252 (2001-06-01), None
patent: 587040 (1977-04-01), None
patent: 3536560 (1986-04-01), None
patent: 19606897 (1997-08-01), None
patent: 0048558 (1982-03-01), None
patent: 0139535 (1985-05-01), None
patent: 0147021 (1985-07-01), None
patent: 0 253 662 (1988-01-01), None
patent: 1040841 (2000-10-01), None
patent: 1 066 830 (2001-01-01), None
patent: 1201247 (2002-05-01), None
patent: 1247524 (2002-10-01), None
patent: 2165752 (1986-04-01), None
patent: 60-105618 (1985-06-01), None
patent: 61-000017 (1986-01-01), None
patent: 63-72626 (1988-04-01), None
patent: 5-500973 (1993-02-01), None
patent: 5-505615 (1993-08-01), None
patent: 2000-300661 (2000-10-01), None
patent: 2000-516196 (2000-12-01), None
patent: 2001-10976 (2001-01-01), None
patent: 2002-326936 (2002-11-01), None
patent: WO 88/05301 (1988-07-01), None
patent: WO 91/13628 (1991-09-01), None
patent: WO 92/00743 (1992-01-01), None
patent: WO 95/18638 (1995-07-01), None
patent: WO 95/30423 (1995-11-01), None
patent: WO 97/25052 (1997-07-01), None
patent: WO 98/28027 (1998-07-01), None
patent: WO 98/39354 (1998-09-01), None
patent: WO 98/52572 (1998-11-01), None
patent: WO 99/06114 (1999-02-01), None
patent: WO 00/01391 (2000-01-01), None
patent: WO 01/39762 (2001-06-01), None
patent: WO 01/39763 (2001-06-01), None
patent: WO 02/07810 (2002-01-01), None
University of Florida Shands Cancer Center (www.ufscc.ufl.edu/Patient/content.aspx (pp. 1-3) (2006).
Braumann et al (Clinical Exper. Metastasis) 2003;20(5):387-94.
Wicki et al. (“Taurolin: A New Concept in Antimicrobial Chemotherapy in Surgical Infection” Urban and Scwarzenbern, vol. 111, pp. 244-253).
http://www.nlm.nih.gov/medlineplus/ency/article/002467.htm Jun. 9, 2001.
van Gelder Neurochemical Research, 8(5) 1983, 687-699.
Gavrovskaya et al., Institute of Experimental Medicine, the Russian Academy of Medical Sciences, St.Petersburg 197376, Russia (523-528).
Braumann et al. (Clinical & Exp. Matastasis, 2003, 20;387-394).
Lubec et al. Life Sciences 58: 2317-2325 (1996).
Canadian Office Action, Application No. CA 2 379 734 dated Sep. 29, 2008.
Japanese Office entitled “Preliminary Notice of Reasons for Rejection”, Dec. 4, 2008, and English language translation, pp. 1-7.
European Search Report from EP appln. No. 01 30 9983 dated Apr. 9, 2003, 4 pages.
Ananthan, inCancer Chemotherapeutic Agents, Foye (Ed.),American Chem. Soc., Washington, D.C. (1995) pp. 49-58.
Anderson et al., “The Role of cytokines, Adhesion Molecules, and Chemokines in Interleukin-2-induced Lymphocytic Infiltration in C57BL/6 Mice”J. Clin. Inv.97: 1952-1959, 1996.
Anonymous, “Cerebrospinal Fluid” http://uscneurosurgery.com/infonet/glossary/c/cerebrospinal%20/fluid%20csf.htm. 2 pages. Accessed May 31, 2007.
Anonymous, “Methods of Sterilisation.”British Pharmacopoeia. vol. 2, Appendix XVIII: A264-A267, 1998.
Anonymous, “Taurolin Suppresses Activity of Tumor Necrosis Factor-α in vivo” Institute of Pharmacology, University of Zurich, Research Report, 1-9, 1993.
Araki et al.,J. Jap. Soc. Gastroenterol. Surg.27(5): 1090-1093, 1994.
Bedrosian, I., et al., “Taurolidine, an Analogue of the Amino Acid Taurine, Suppresses Interleukin 1 and Tumor Necrosis Factor Synthesis in Human Peripheral Blood Mononuclear Cells” Cytokine vol. 3, No. 6 (Nov.) 1991: 568-575.
Blenkharn, “The Antimicrobial Activity of Taurolin® —a Possible New Additive for Parenteral Nutrition Solutions”Clin. Nutr.6(1): 35-38, 1987.
Blum et al., “Hexamethylmelamine—A New Drug with Activity in Solid Tumors”Eur. J. Cancer, 9:195-202, 1973.
Bobrich et al., “Influence of intraperitoneal application of taurolidine/heparin on expression of adhesion molecules and colon cancer in rats undergoing laparoscopy”J. Surg. Res.137(1):75-82, 2007.
Braumann et al., “The Influence of Intraoperative Intravenous and Intraperitoneal Application of Taurolidine with Hep
Ed. Geistlich Soehne AG Fuer Chemische Industrie
Fetterolf Brandon
Gembeh Shirley V
Rothwell Figg Ernst & Manbeck P.C.
LandOfFree
Treatment of cancers with methylol-containing compounds and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of cancers with methylol-containing compounds and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of cancers with methylol-containing compounds and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282421